調査レポート | • レポートコード：GIR-2104Z10044 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、非侵襲的がん診断のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。非侵襲的がん診断の種類別市場規模（臨床化学、免疫化学/イムノアッセイ、分子診断、その他）、用途別市場規模（固形腫瘍、血液がん、肺がん、乳がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・非侵襲的がん診断の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Precision Therapeutics, Inc. (U.S.)、A&G Pharmaceutical, Inc. (U.S.)、Affymetrix Inc. (U.S.)、AVIVA Biosciences Corporation (U.S.)、BIOVIEW Inc. (U.S.)、Laboratory Corporation of America Holdings (LabCorp) (U.S.)、Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)、Digene Corporation (U.S.)、Gen-Probe Incorporated (U.S.)、IVDiagnostics, Inc. (U.S.) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：臨床化学、免疫化学/イムノアッセイ、分子診断、その他 ・用途別分析2016年-2026年：固形腫瘍、血液がん、肺がん、乳がん、その他 ・非侵襲的がん診断の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・非侵襲的がん診断のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・非侵襲的がん診断のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・非侵襲的がん診断の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・非侵襲的がん診断の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Noninvasive Cancer Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Noninvasive Cancer Diagnostics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Noninvasive Cancer Diagnostics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Noninvasive Cancer Diagnostics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Clinical Chemistry
Immunochemistry/Immunoassay
Molecular Diagnostics
Others
Market segment by Application, can be divided into
Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others
Market segment by players, this report covers
Precision Therapeutics, Inc. (U.S.)
A&G Pharmaceutical, Inc. (U.S.)
Affymetrix Inc. (U.S.)
AVIVA Biosciences Corporation (U.S.)
BIOVIEW Inc. (U.S.)
Laboratory Corporation of America Holdings (LabCorp) (U.S.)
Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
Digene Corporation (U.S.)
Gen-Probe Incorporated (U.S.)
IVDiagnostics, Inc. (U.S.)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Noninvasive Cancer Diagnostics
1.2 Classification of Noninvasive Cancer Diagnostics by Type
1.2.1 Overview: Global Noninvasive Cancer Diagnostics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Noninvasive Cancer Diagnostics Revenue Market Share by Type in 2020
1.2.3 Clinical Chemistry
1.2.4 Immunochemistry/Immunoassay
1.2.5 Molecular Diagnostics
1.2.6 Others
1.3 Global Noninvasive Cancer Diagnostics Market by Application
1.3.1 Overview: Global Noninvasive Cancer Diagnostics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Solid Tumors
1.3.3 Blood Cancer
1.3.4 Lung Cancer
1.3.5 Breast Cancer
1.3.6 Others
1.4 Global Noninvasive Cancer Diagnostics Market Size & Forecast
1.5 Global Noninvasive Cancer Diagnostics Market Size and Forecast by Region
1.5.1 Global Noninvasive Cancer Diagnostics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Noninvasive Cancer Diagnostics Market Size by Region, (2016-2021)
1.5.3 North America Noninvasive Cancer Diagnostics Market Size and Prospect (2016-2026)
1.5.4 Europe Noninvasive Cancer Diagnostics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Noninvasive Cancer Diagnostics Market Size and Prospect (2016-2026)
1.5.6 South America Noninvasive Cancer Diagnostics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Noninvasive Cancer Diagnostics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Noninvasive Cancer Diagnostics Market Drivers
1.6.2 Noninvasive Cancer Diagnostics Market Restraints
1.6.3 Noninvasive Cancer Diagnostics Trends Analysis
2 Company Profiles
2.1 Precision Therapeutics, Inc. (U.S.)
2.1.1 Precision Therapeutics, Inc. (U.S.) Details
2.1.2 Precision Therapeutics, Inc. (U.S.) Major Business
2.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.1.4 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Precision Therapeutics, Inc. (U.S.) Recent Developments and Future Plans
2.2 A&G Pharmaceutical, Inc. (U.S.)
2.2.1 A&G Pharmaceutical, Inc. (U.S.) Details
2.2.2 A&G Pharmaceutical, Inc. (U.S.) Major Business
2.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.2.4 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 A&G Pharmaceutical, Inc. (U.S.) Recent Developments and Future Plans
2.3 Affymetrix Inc. (U.S.)
2.3.1 Affymetrix Inc. (U.S.) Details
2.3.2 Affymetrix Inc. (U.S.) Major Business
2.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.3.4 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Affymetrix Inc. (U.S.) Recent Developments and Future Plans
2.4 AVIVA Biosciences Corporation (U.S.)
2.4.1 AVIVA Biosciences Corporation (U.S.) Details
2.4.2 AVIVA Biosciences Corporation (U.S.) Major Business
2.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.4.4 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 AVIVA Biosciences Corporation (U.S.) Recent Developments and Future Plans
2.5 BIOVIEW Inc. (U.S.)
2.5.1 BIOVIEW Inc. (U.S.) Details
2.5.2 BIOVIEW Inc. (U.S.) Major Business
2.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.5.4 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 BIOVIEW Inc. (U.S.) Recent Developments and Future Plans
2.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
2.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Details
2.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Major Business
2.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Developments and Future Plans
2.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
2.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Details
2.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Major Business
2.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Developments and Future Plans
2.8 Digene Corporation (U.S.)
2.8.1 Digene Corporation (U.S.) Details
2.8.2 Digene Corporation (U.S.) Major Business
2.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.8.4 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Digene Corporation (U.S.) Recent Developments and Future Plans
2.9 Gen-Probe Incorporated (U.S.)
2.9.1 Gen-Probe Incorporated (U.S.) Details
2.9.2 Gen-Probe Incorporated (U.S.) Major Business
2.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.9.4 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Gen-Probe Incorporated (U.S.) Recent Developments and Future Plans
2.10 IVDiagnostics, Inc. (U.S.)
2.10.1 IVDiagnostics, Inc. (U.S.) Details
2.10.2 IVDiagnostics, Inc. (U.S.) Major Business
2.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
2.10.4 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 IVDiagnostics, Inc. (U.S.) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Noninvasive Cancer Diagnostics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Noninvasive Cancer Diagnostics Players Market Share
3.2.2 Top 10 Noninvasive Cancer Diagnostics Players Market Share
3.2.3 Market Competition Trend
3.3 Noninvasive Cancer Diagnostics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Noninvasive Cancer Diagnostics Revenue and Market Share by Type (2016-2021)
4.2 Global Noninvasive Cancer Diagnostics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Noninvasive Cancer Diagnostics Revenue Market Share by Application (2016-2021)
5.2 Noninvasive Cancer Diagnostics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Noninvasive Cancer Diagnostics Revenue by Type (2016-2026)
6.2 North America Noninvasive Cancer Diagnostics Revenue by Application (2016-2026)
6.3 North America Noninvasive Cancer Diagnostics Market Size by Country
6.3.1 North America Noninvasive Cancer Diagnostics Revenue by Country (2016-2026)
6.3.2 United States Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
6.3.3 Canada Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
6.3.4 Mexico Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Noninvasive Cancer Diagnostics Revenue by Type (2016-2026)
7.2 Europe Noninvasive Cancer Diagnostics Revenue by Application (2016-2026)
7.3 Europe Noninvasive Cancer Diagnostics Market Size by Country
7.3.1 Europe Noninvasive Cancer Diagnostics Revenue by Country (2016-2026)
7.3.2 Germany Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
7.3.3 France Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
7.3.5 Russia Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
7.3.6 Italy Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Type (2016-2026)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Application (2016-2026)
8.3 Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region
8.3.1 Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Region (2016-2026)
8.3.2 China Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
8.3.3 Japan Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
8.3.4 South Korea Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
8.3.5 India Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
8.3.7 Australia Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Noninvasive Cancer Diagnostics Revenue by Type (2016-2026)
9.2 South America Noninvasive Cancer Diagnostics Revenue by Application (2016-2026)
9.3 South America Noninvasive Cancer Diagnostics Market Size by Country
9.3.1 South America Noninvasive Cancer Diagnostics Revenue by Country (2016-2026)
9.3.2 Brazil Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
9.3.3 Argentina Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Type (2016-2026)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Application (2016-2026)
10.3 Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country
10.3.1 Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Country (2016-2026)
10.3.2 Turkey Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
10.3.4 UAE Noninvasive Cancer Diagnostics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Noninvasive Cancer Diagnostics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Noninvasive Cancer Diagnostics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Noninvasive Cancer Diagnostics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Noninvasive Cancer Diagnostics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Noninvasive Cancer Diagnostics Revenue Market Share by Region (2021-2026)
Table 6. Precision Therapeutics, Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 7. Precision Therapeutics, Inc. (U.S.) Major Business
Table 8. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 9. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. A&G Pharmaceutical, Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 11. A&G Pharmaceutical, Inc. (U.S.) Major Business
Table 12. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 13. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Affymetrix Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 15. Affymetrix Inc. (U.S.) Major Business
Table 16. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 17. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. AVIVA Biosciences Corporation (U.S.) Corporate Information, Head Office, and Major Competitors
Table 19. AVIVA Biosciences Corporation (U.S.) Major Business
Table 20. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 21. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. BIOVIEW Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 23. BIOVIEW Inc. (U.S.) Major Business
Table 24. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 25. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Corporate Information, Head Office, and Major Competitors
Table 27. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Major Business
Table 28. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 29. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 31. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Major Business
Table 32. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 33. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Digene Corporation (U.S.) Corporate Information, Head Office, and Major Competitors
Table 35. Digene Corporation (U.S.) Major Business
Table 36. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 37. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Gen-Probe Incorporated (U.S.) Corporate Information, Head Office, and Major Competitors
Table 39. Gen-Probe Incorporated (U.S.) Major Business
Table 40. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 41. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. IVDiagnostics, Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 43. IVDiagnostics, Inc. (U.S.) Major Business
Table 44. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product and Solutions
Table 45. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Noninvasive Cancer Diagnostics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Noninvasive Cancer Diagnostics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Noninvasive Cancer Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Noninvasive Cancer Diagnostics Players Head Office, Products and Services Provided
Table 50. Noninvasive Cancer Diagnostics Mergers & Acquisitions in the Past Five Years
Table 51. Noninvasive Cancer Diagnostics New Entrants and Expansion Plans
Table 52. Global Noninvasive Cancer Diagnostics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Noninvasive Cancer Diagnostics Revenue Share by Type (2016-2021)
Table 54. Global Noninvasive Cancer Diagnostics Revenue Forecast by Type (2021-2026)
Table 55. Global Noninvasive Cancer Diagnostics Revenue by Application (2016-2021)
Table 56. Global Noninvasive Cancer Diagnostics Revenue Forecast by Application (2021-2026)
Table 57. North America Noninvasive Cancer Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Noninvasive Cancer Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Noninvasive Cancer Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Noninvasive Cancer Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Noninvasive Cancer Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Noninvasive Cancer Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Noninvasive Cancer Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Noninvasive Cancer Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Noninvasive Cancer Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Noninvasive Cancer Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Noninvasive Cancer Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Noninvasive Cancer Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Noninvasive Cancer Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Noninvasive Cancer Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Noninvasive Cancer Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Noninvasive Cancer Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Noninvasive Cancer Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Noninvasive Cancer Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Noninvasive Cancer Diagnostics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Picture
Figure 2. Global Noninvasive Cancer Diagnostics Revenue Market Share by Type in 2020
Figure 3. Clinical Chemistry
Figure 4. Immunochemistry/Immunoassay
Figure 5. Molecular Diagnostics
Figure 6. Others
Figure 7. Noninvasive Cancer Diagnostics Revenue Market Share by Application in 2020
Figure 8. Solid Tumors Picture
Figure 9. Blood Cancer Picture
Figure 10. Lung Cancer Picture
Figure 11. Breast Cancer Picture
Figure 12. Others Picture
Figure 13. Global Noninvasive Cancer Diagnostics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Noninvasive Cancer Diagnostics Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Noninvasive Cancer Diagnostics Revenue Market Share by Region (2016-2026)
Figure 16. Global Noninvasive Cancer Diagnostics Revenue Market Share by Region in 2020
Figure 17. North America Noninvasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Noninvasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Noninvasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Noninvasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Noninvasive Cancer Diagnostics Market Drivers
Figure 22. Noninvasive Cancer Diagnostics Market Restraints
Figure 23. Noninvasive Cancer Diagnostics Market Trends
Figure 24. Precision Therapeutics, Inc. (U.S.) Recent Developments and Future Plans
Figure 25. A&G Pharmaceutical, Inc. (U.S.) Recent Developments and Future Plans
Figure 26. Affymetrix Inc. (U.S.) Recent Developments and Future Plans
Figure 27. AVIVA Biosciences Corporation (U.S.) Recent Developments and Future Plans
Figure 28. BIOVIEW Inc. (U.S.) Recent Developments and Future Plans
Figure 29. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Developments and Future Plans
Figure 30. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Developments and Future Plans
Figure 31. Digene Corporation (U.S.) Recent Developments and Future Plans
Figure 32. Gen-Probe Incorporated (U.S.) Recent Developments and Future Plans
Figure 33. IVDiagnostics, Inc. (U.S.) Recent Developments and Future Plans
Figure 35. Global Noninvasive Cancer Diagnostics Revenue Share by Players in 2020
Figure 36. Noninvasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players Noninvasive Cancer Diagnostics Revenue Market Share in 2020
Figure 38. Global Top 10 Players Noninvasive Cancer Diagnostics Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global Noninvasive Cancer Diagnostics Revenue Share by Type in 2020
Figure 41. Global Noninvasive Cancer Diagnostics Market Share Forecast by Type (2021-2026)
Figure 42. Global Noninvasive Cancer Diagnostics Revenue Share by Application in 2020
Figure 43. Global Noninvasive Cancer Diagnostics Market Share Forecast by Application (2021-2026)
Figure 44. North America Noninvasive Cancer Diagnostics Sales Market Share by Type (2016-2026)
Figure 45. North America Noninvasive Cancer Diagnostics Sales Market Share by Application (2016-2026)
Figure 46. North America Noninvasive Cancer Diagnostics Revenue Market Share by Country (2016-2026)
Figure 47. United States Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe Noninvasive Cancer Diagnostics Sales Market Share by Type (2016-2026)
Figure 51. Europe Noninvasive Cancer Diagnostics Sales Market Share by Application (2016-2026)
Figure 52. Europe Noninvasive Cancer Diagnostics Revenue Market Share by Country (2016-2026)
Figure 53. Germany Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Noninvasive Cancer Diagnostics Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific Noninvasive Cancer Diagnostics Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Share by Region (2016-2026)
Figure 61. China Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Noninvasive Cancer Diagnostics Sales Market Share by Type (2016-2026)
Figure 68. South America Noninvasive Cancer Diagnostics Sales Market Share by Application (2016-2026)
Figure 69. South America Noninvasive Cancer Diagnostics Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa Noninvasive Cancer Diagnostics Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa Noninvasive Cancer Diagnostics Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE Noninvasive Cancer Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
世界の非侵襲的癌診断市場規模・現状・予測（2021年-2027年） Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to gen…- 世界の非侵襲的出生前診断市場規模・現状・予測（2021年-2027年） Noninvasive Prenatal Diagnostics detect a variety of chromosomal disorders such as Down's syndrome, Edwards syndrome, Turner syndrome and Pato syndrome. North America has the largest share of the noninvasive prenatal diagnostics market, with Asia Pacific and the Middle East achieving the fastest gro…
- 世界の非侵襲診断市場 2021：企業別、地域別、種類・用途別 The Noninvasive Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界の結腸直腸がん分子診断市場規模・現状・予測（2021年-2027年） Colorectal cancer molecular diagnostics can speed up the identification of colorectal cancer to provide patients with more treatment options. Individualized and targeted treatments are reshaping the colorectal molecular diagnostics market. Molecular pathology is a key factor to personalized medicine…
- 世界の頭頸部がん診断市場規模・現状・予測（2021年-2027年） Head and neck cancer begins in squamous cells that line the mucosal surfaces of the head and neck such as, inside the mouth, the nose, and the throat. The head and neck cancers include specific areas of the body such as oral cavity, pharynx, larynx, paranasal sinuses and nasal cavity, and salivary g…